results

Last reviewed 01/2018

The proportions of patients who had a recurrence of atrial fibrillation after a mean follow-up of 16 months were:

  • 35% for amiodarone
  • 63% for sotalol/propafenone
  • p < 0.001

Amiodarone resulted in a higher rate of adverse events necessitating discontinuation of therapy:

  • 18% for amiodarone
  • 11% for sotalol/propafenone
  • p = 0.06